1008361-80-5

Basic information

• Product Name: 4-broMo-3-chloro-benzene-l,2-diaMine
• Synonyms: 4-broMo-3-chloro-benzene-l,2-diaMine;4-BROMO-3-CHLORO-1-2-BENZENEDIAMINE
• CAS NO: 1008361-80-5
• Molecular Formula: C₆H₆BrClN₂
• Molecular Weight: 221.48224
• Mol File: 1008361-80-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 315.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.813±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.40±0.10(Predicted)
• CAS DataBase Reference: 4-broMo-3-chloro-benzene-l,2-diaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-3-chloro-benzene-l,2-diaMine(1008361-80-5)
• EPA Substance Registry System: 4-broMo-3-chloro-benzene-l,2-diaMine(1008361-80-5)

Safety Data

• Hazardous Substances Data: 1008361-80-5(Hazardous Substances Data)

Usage

General Description

4-bromo-3-chloro-benzene-1,2-diamine is a chemical compound having the molecular formula C6H6BrClN2. As suggested by its name, it is a derivative of benzene, featuring both bromo and chloro substituents, along with two amine groups. Given its structure, this compound is likely to have reactivity characteristic of amines and halogenated aromatics. It is generally categorized under the class of organobromides, organochlorides, and organonitrogen compounds. The compound does not have widely reported uses and its physical and chemical properties, such as solubility, melting point and boiling point, are not widely documented. The safety and potential health effects of this compound have not been thoroughly researched and are not broadly known.

Upstream product

• 1000573-99-8 4-bromo-3-chloro-2-nitro aniline 
• 59483-54-4 3-chloro-2-nitro-aniline 

Downstream Products

• 1210047-63-4 6-bromo-5-chloroquinoxaline 
• 1008361-81-6 5-bromo-4-chloro-1H-benzoimidazole 

Relevant articles and documents

COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.